Alexion exchanges stock for 1.375% convertibles owned by Citadel

By Susanna Moon

Chicago, April 9 - Alexion Pharmaceuticals, Inc. issued 3,021,094 common shares on April 9 in exchange for $46.73 million principal amount of its 1.375% convertible senior notes due 2012 beneficially owned by Citadel Equity Fund Ltd., according to an 8-K filing with the Securities and Exchange Commission.

After the exchange, the outstanding principal balance of the notes is $50,492,000.

The company said it may offer additional exchanges as opportunities arise.

Alexion is a Cheshire, Conn.-based biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.